Transplantation is invariably associated with programmed cell death including apop- 
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animal models: murine, basic (laboratory) research/science, cell death, cell death: apoptosis, cellular biology, graft survival, heart transplantation/cardiology, immunohistochemistry, molecular biology forms of programmed cell death, including necrosis and apoptosis.
Apoptosis is primarily mediated by a cascade of caspases resulting in double-stranded DNA breaks and plasma membrane blebbing.
Necrosis, on the other hand, promotes cellular swelling, plasma membrane rupture, and the release of proinflammatory molecules.
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The most investigated pathway of regulated necrosis, termed necroptosis, is initiated by the receptor-interacting protein kinase family (RIPK1 and RIPK3). [1] [2] [3] While caspase-8 induces apoptosis, we now understand that it also serves as a major regulator of necroptosis through its ability to cleave RIPK1 and RIPK3. 4, 5 Under caspase-8 inhibition, RIPK1/3 can activate mixed-lineage kinase domain-like protein (MLKL), which, on activation, is recruited to the inner cell membrane to form a lethal pore, inducing membrane rupture and cell death. [6] [7] [8] [9] Mitochondria are the primary cellular energy-producing organelles, and they play a central role in cell injury. Opening of the mitochondrial permeability transition pore (mPTP) in response to ischemia-reperfusion injury has been linked to cell death in the heart and other organs. Prolonged opening of mPTPs is linked to mitochondrial swelling and release of apoptotic molecules.
Mitochondrial permeability is largely regulated by cyclophilin D
(Cyp-D). 10 Cyp-D mediates a conformational change of adenine nucleotide translocase, leading to mitochondrial swelling and release of apoptogenic effectors, which leads to cell death. 11 The involvement of mitochondria and mPTPs as downstream necroptotic mediators is still a point of contention. [12] [13] [14] While it is well established that mitochondria are platforms for apoptosis execution, the prospect of direct mitochondrial involvement in programmed necrosis remains controversial, and contradictory experiments point toward either mitochondria-dependent or -independent forms of necrosis or necroptosis.
12-17
In our previous studies, we demonstrated that RIPK3-mediated necroptosis in donor heart and kidney grafts can promote inflammatory injury and transplant rejection. [18] [19] [20] Thus, eliminating RIPK3 expression in mouse heart and kidney cells or cardiac and renal allografts attenuated cell and tissue necrosis, diminished release of cell damage-associated molecular patterns (CDAMP), and reduced early graft injury and rejection. [18] [19] [20] [21] In the current study, we demonstrate that Cyp-D is an important mechanistic mediator of necroptosis in MVECs and, importantly, we
show that Cyp-D is an effective target for the prevention of cardiac transplant rejection.
| MATERIAL S AND ME THODS

| Animals
Male inbred C57BL/6 (B6), BALB/c mice, and B6.Cyp-D −/− mice (The Jackson Laboratory, Bar Harbor, ME) were maintained at the animal facility at Western University. All experimental procedures were approved by the Animal Use Committee of Western University.
| Heterotopic cardiac transplant and postoperative monitoring
Donor cardiac grafts were perfused with saline to remove blood after being anesthetized with the mixture ketamine/xylazine according to the approved animal protocol. The inferior vena cava and dorsal aorta were then clamped above and below the cardiac graft. The graft was then removed, and intra-abdominal heterotopic cardiac transplants were performed in our microsurgery laboratory in accordance with an approved protocol. The recipient received sirolimus [rapamycin] (LC Laboratories, Woburn, MA) from day 0 to day 9 posttransplant
(1 mg/kg mouse). Pulsation of the cardiac graft was monitored daily.
Cessation of pulsation was defined as the end point of rejection.
| Histology and immunohistochemistry
We analyzed the grafts harvested from beating wild-type and Nikon Instruments, NY).
All injury scores were evaluated by a pathologist in a blinded manner. Graft injury was evaluated based on change in endothelium compared with naïve condition. Damage was scored on a scale of 0-4 (0, no change; 1, 0-24% change; 2, 25-49% change; 3, 50-74% change; 4, >75% change). 
| Cell death assay
| Immunoblot analyses
MVECs were grown to a confluent monolayer and treated as de- To analyze HMGB1 in heart grafts, the samples were prepared in lysis buffer with electric homogenizer followed by centrifugation.
The supernatants were collected for HMGB1 and GAPDH Western blotting.
| shRNA-mediated Cyp-D RNA silencing and real-time PCR
Cyp-D shRNA (Dharmacon, Lafayette, CO) was transfected into MVECs by using Lipofectamine (Invitrogen, Waltham, MA).
Puromycin (Sigma-Aldrich) was used for antibiotic selection to eliminate untransfected MVECs. Cyp-D gene silencing was confirmed by real-time PCR.
Total RNA from wild-type or shRNA-transfected MVECs was extracted from tissue or cells through TRIzol extraction (Invitrogen).
cDNA was generated from RNA using Superscript II (Thermo Fisher 
| Statistical analyses
Data were analyzed by using the Student's t test for unpaired values.
The Mantel-Cox log rank test was used to determine graft survival differences. Differences were considered significant when P ≤ .05.
| RE SULTS
| Mitochondrial permeability participates in MVEC necroptosis
We used wild-type and RIPK3-deficient endothelial cells to deter- MVECs. S-15176 prevents collapse of the electrochemical gradient across the mitochondrial membrane and inhibits release of apoptotic molecules. 22, 23 We found that the addition of S-15176
to TNFα + IETD-treated MVECs significantly reduced necroptosis ( Figure 1B ).
Opening of mPTPs is largely regulated by Cyp-D. 10 Cyp-D may regulate apoptotic cell death as well as necrotic cell death. 10 It has been shown that Cyp-D deficiency in mouse embryonic fibroblast cells resulted in a partial rescue of necroptotic cell death in vitro. 24 However, another study showed that RIKP1/3 and the mPTP/Cyp-D mediate 2 distinct death pathways. 25 We studied the role Cyp-D in MVEC necroptosis. At first, we used CsA, a calcineurin inhibitor and CsA ( Figure 3A, B) . These data support the finding that necroptosis is regulated by Cyp-D.
| ROS and caspase-3 and -9 do not contribute to MVEC necroptosis
Next, we studied the downstream mechanism of Cyp-D-mediated necroptosis. The opening of mPTPs results in ROS release and activation of caspase-9 and its downstream caspase-3.
Recent studies showed that ROS plays a crucial role in necrosis and, thus, inhibition of ROS prevents TNFα-induced necroptotic cell death. [28] [29] [30] [31] [32] In our study, the addition of caspase-3 inhibitor (DEVD) or caspase-9 inhibitor (LEHD) did not attenuate TNFα-induced necroptosis ( Figure 4A ). The addition of ROS inhibitors
Tempol and NAC did not inhibit necroptosis in MVECs ( Figure 4B ).
Similarly, mitochondria-specific ROS inhibitor Mito-TEMPO did not inhibit necroptosis ( Figure 4C ). These data suggest that ROS and caspase-3 and -9 do not play a significant role in cardiac endothelial cell necroptosis.
| Cyp-D-mediated necroptosis is linked to MLKL activation
MLKL is phosphorylated by RIPK3 and then migrates to lipid rafts, where it forms a pore, ultimately resulting in cell membrane rupture-a characteristic feature of necroptosis. 
| Cyp-D deficiency in donor cardiac grafts attenuates rejection
Our data indicate that Cyp-D may be an effective target to inhibit cell death. To determine if Cyp-D deficiency in donor cardiac grafts can improve transplant survival, we performed heterotopic transplant of wild-type B6 or Cyp-D −/− hearts into BALB/c mice followed by brief immunosuppression (0-9 days) with sirolimus (rapamycin).
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Cyp-D −/− grafts survived significantly longer posttransplant compared with wild-type C57BL/6 grafts (89 ± 43 vs 29 ± 6 days, n = 7, P < .0001) ( Figure 6A ).
To assess graft injury, we collected the cohort grafts, which were still beating 28 days posttransplant. Grafts were analyzed by the use of Western blotting, histology, and immunohistochemistry. analyzed for pMLKL by Western blotting using anti-phospho-S345 MLKL. Antibodies against total MLKL and GAPDH were used as controls. F, Protein was quantitated by densitometry (Alphaview; ProteinSimple) and normalized using GAPDH. Western blotting results from 3 repeated cell death assays were pooled. Data are shown as mean ± SD *P < .05, **P < .01, ***P < .001, t test Cyp-D has been considered as an effective target against apoptosis and heart ischemia-reperfusion injury. [33] [34] [35] [36] [37] [38] Interestingly, inhibition of Cyp-D by a CsA analogue NIM811 showed a protective effect on cardiomyocyte apoptosis and T cell infiltration, although acute cardiac graft rejection was not altered. 39, 40 Cyclosporine has been proved to be an effective immunosuppressive drug in transplantation. However, it can inhibit calcineurin and Cyp-D function.
Our data hint that the effectiveness of cyclosporine treatment in transplantation is not only because of its immunosuppressive function but also because of its inhibition of necroptosis in the graft.
The involvement of mitochondrial molecules in necroptosis is still controversial. [12] [13] [14] [15] [16] [17] This may be due to the fact that different cell types were used in different studies, and not all cells can undergo necroptosis, because parenchymal cells differ in gene expression and cellular signaling cascades. Indeed, organ-specific expressions of necrosis-related molecules have been described in mice and humans. 41, 42 In our study, we found that Cyp-D participates in MVEC necroptosis (Figures 1 and 2) . Hence, Cyp-D might be an effective target of transplants considering its role in apoptosis and heterotopically transplanted into the abdomens of BALB/c mice, followed by rapamycin (Rap) treatment (1 mg/kg, days 0-9). Grafts were palpated and scored daily and considered rejected when pulsation ceased (n = 4 or 7, ***P < .0001, Mantel-Cox log rank test). B, To assess graft injury, the cohort grafts were collected 28 days posttransplant and treated with lysis buffer. Supernatants were used for Western blotting. Released HMGB1 protein was detected with anti-HMGB1. Anti-GAPDH was used as control. C, Protein was quantitated by densitometry (Alphaview; ProteinSimple) and normalized by using GAPDH. Data are pooled from four grafts and shown as mean ± SD. **P ≤ .01, t test Even though our data suggested that Cyp-D participates in necroptosis (Figures 1 and 2) , it is unclear how TNFα and caspase-8 inhibition leads to the opening of mPTPs. In Figure 9 , we illustrated several possible pathways for cell death. MLKL has been shown to translocate to the plasma membrane to induce membrane breakage and release of CDAMPs. Alternatively, the RIPK1/3-MLKL complex may activate protein phosphoglycerate mutases 5 (PGAM5).
PGAM5 activates the hydrolase function of dynamin-related protein 1 (Drp1). well as MLKL phosphorylation, which we will study.
In conclusion, our findings suggest that mPTPs play an important role in necroptotic death of cardiac cells and graft rejection. Hence, Cyp-D might be an effective target to promote long-term graft survival and transplant tolerance in addition to immune suppression.
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